Sort   by:  
 Page size 
UnknownTargeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Not available
S-EPMC6075827 | biostudies-literature
UnknownPhase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
Not available
S-EPMC5959197 | biostudies-literature
UnknownQuality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
Not available
S-EPMC5891128 | biostudies-literature
UnknownChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Not available
S-EPMC5891129 | biostudies-literature
UnknownCabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Not available
S-EPMC4383838 | biostudies-literature
UnknownCirculating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Not available
S-EPMC3970171 | biostudies-literature
UnknownSeven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Not available
S-EPMC5805480 | biostudies-literature
UnknownCabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Not available
S-EPMC4110249 | biostudies-literature
UnknownTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Not available
S-EPMC4872347 | biostudies-literature
Sort   by:  
 Page size